The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to ...
The Federal Trade Commission is stepping up its crackdown on so-called "junk patents," which it contends are ploys intended ...
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, ...
disputing the accuracy of some 300 patent listings in the Food and Drug Administration’s so-called “Orange Book.” The crackdown, which comes six months after FTC challenged 10 pharma majors in a ...
The FTC is investigating improper patent listings, including Novo Nordisk's Ozempic, which could impact shareholders. Novo Nordisk's GLP-1 agonists, including Ozempic, have become a significant ...
Boehringer Ingelheim, one of 10 companies sent a warning letter by the FTC disputing the accuracy of patent listings in the ...
voiced support for the U.S. Federal Trade Commission (FTC) taking action this week to challenge several major pharmaceutical companies, including GSK, for anticompetitive use of so-called junk ...
In a warning letter sent to several drugmakers, including Ozempic's Denmark-based manufacturer Novo Nordisk, the FTC announced that it plans to challenge so-called "junk patents" that keep the ...
"By filing bogus patent listings, pharma companies block competition and inflate the cost of prescription drugs, forcing Americans to pay sky-high prices for medicines they rely on," said FTC chair ...